Low PCDH17 expression still negatively impacts survival in the FLT3-ITD wild-type, NPM1 mutated, and TP53 absent patient subsets, suggesting that PCDH17 expression status could further refine the molecular classification of subsets of AML patients with or without specific mutations. This evidence concerns the gene TP53 and acute myeloid leukemia.